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Introduction
In mammalian cells, mitochondria activate the apoptotic execu-
tion machinery. Apoptotic stimuli induce mitochondrial outer 
membrane permeability and the release of proapoptotic proteins 
such as cytochrome c (Cyt c) into the cytosol. The collective ac-
tion of these molecules results in effector caspase activation and 
apoptotic cell death (Wang, 2001). Mitochondrial permeabiliza-
tion is controlled by the Bcl-2 protein family, which comprises 
the antiapoptotic Bcl-2 subfamily and the proapoptotic Bax/Bak 
and Bcl-2 homology 3 (BH3) domain–only subfamilies (Adams 
and Cory, 1998). Their functional activity relies on homo- and 
heterodimerization, which proceeds by interaction of the BH3 
domain α helix with a groove formed by the BH1 and 2 domains 
(Sattler et al., 1997).
The BH3 domain–only subfamily has many members 
that specialize in responsiveness to specifi  c apoptotic stimuli 
(Puthalakath and Strasser 2002). BH3-only proteins require Bax or 
Bak to induce cell death. They induce assembly of Bax/Bak into 
homomultimers in the mitochondrial outer membrane (Wei et al., 
2000; Kuwana et al., 2002). These multimers are postulated to 
either form transmembrane pores themselves or to facilitate pore 
formation. Inhibitory Bcl-2 family members sequester only BH3 
and/or Bax/Bak proteins, thereby preventing their participation 
in proapoptotic complexes (Cheng et al., 2001).
The BH3 domain–only protein Bid conveys the apoptotic 
signal from death receptors, such as TNF receptor 1, TNF-related 
apoptosis-inducing ligand (TRAIL) receptors, and Fas/CD95 to 
mitochondria (Li et al., 1998; Luo et al., 1998). Upon ligand 
binding, these death receptors induce formation of a complex be-
tween the intracellular adaptor Fas-associated death domain and 
procaspase-8 or -10. This results in increased local concentrations 
of these inducer caspases, which leads to their activation (Boatright 
and Salvesen, 2003). Active caspase-8/10 can cleave and acti-
vate Bid as well as effector caspases. In certain cell types, the 
mitochondrial route is dispensable for death receptor–induced 
apoptosis, whereas in others it constitutes an essential amplifi  -
cation loop for effector caspase activation (Yin et al., 1999).
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cl-2 family member Bid is subject to autoinhibition; 
in the absence of stimuli, its N-terminal region se-
questers the proapoptotic Bcl-2 homology 3 (BH3) 
domain. Upon proteolytic cleavage in its unstructured 
loop, Bid is activated, although structural data reveal no 
apparent resulting conformational change. We found that, 
upon Bid cleavage, the N-terminal fragment (tBid-N) is 
ubiquitinated and degraded, thus freeing the BH3 do-
main in the C-terminal fragment (tBid-C). Ubiquitination 
of tBid-N is unconventional because acceptor sites are 
neither lysines nor the N terminus. Chemical approaches 
implicated thioester and hydroxyester linkage of ubiquitin 
and mutagenesis implicated serine and possibly threonine 
as acceptor residues in addition to cysteine. Acceptor sites 
reside predominantly but not exclusively in helix 1, which 
is required for ubiquitination and degradation of tBid-N. 
Rescue of tBid-N from degradation blocked Bid’s ability to 
induce mitochondrial outer membrane permeability but 
not mitochondrial translocation of the cleaved complex. 
We conclude that unconventional ubiquitination and 
proteasome-dependent degradation of tBid-N is required 
to unleash the proapoptotic activity of tBid-C.
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The three-dimensional organization of full-length Bid has 
been resolved by nuclear magnetic resonance (NMR; Chou et al., 
1999; McDonnell et al., 1999). Residues 1–12 and 43–77 form 
unstructured loops. The structured portion consists of eight α he-
lices arranged in a compact fold (Fig. S1 A, available at http://
www.jcb.org/cgi/content/full/jcb.200707063/DC1). Of these, 
helix 3 constitutes the BH3 domain, which is fi  xed by hydrophobic 
contacts with helixes 1 and 8. The sites for proteolytic cleavage 
by caspase-8 or granzyme B lie in the second unstructured loop 
(D60 and D75, respectively). In solution, N- and C-terminal frag-
ments of Bid remain associated upon cleavage by caspase-8 and 
the complex undergoes no apparent conformational change (Chou 
et al., 1999; Kudla et al., 2000; Zha et al., 2000). Cleavage gener-
ates an N-terminal glycine in truncated C-terminal Bid (tBid-C) 
that can be myristoylated. This lipid modifi  cation facilitates tar-
geting of tBid-C to mitochondria but is not required for it (Zha 
et al., 2000). Rather, helices 4, 5, and 6 appeared to be the critical 
elements for such targeting, specifi  cally to cardiolipin-enriched 
domains in the mitochondrial membrane (Lutter et al., 2000).
Making the BH3 domain available for interactions with 
the BH1/BH2 groove of other Bcl-2 family members is essential 
for Bid’s proapoptotic function. The solution structure of Bid 
indicates that the BH3 domain must be freed from the structural 
constraint that is exerted by the N-terminal fragment of Bid 
(tBid-N; Chou et al., 1999; McDonnell et al., 1999). Indeed, 
several biochemical studies have shown that tBid-N acts as an 
inhibitor of tBid-C (Tan et al., 1999; Kudla et al., 2000; Renshaw 
et al., 2004). Specifi  cally, Tan et al. (1999) produced compel-
ling evidence for autoinhibition of Bid by interactions between 
helix 2 and the BH3 domain. A mutant full-length Bid protein 
in which these interactions were abrogated was as effective as 
tBid-C in inducing apoptosis and binding to Bcl-xL (Tan et al., 
1999). The natural occurrence of an alternative splice form of 
Bid that lacks the BH3 domain but possesses the inhibitory 
N-terminal sequences lends further support to the idea that this 
is an important mode of tBid-C regulation (Renshaw et al., 2004). 
We have addressed the question of how Bid cleavage can re-
lease tBid-C from inhibition by tBid-N. We reveal that this is 
accomplished by unconventional ubiquitination of the tBid-N 
fragment followed by its proteasomal degradation.
Results
tBid-N disappears upon its generation
To follow the fate of tBid-N and tBid-C, Bid was N-terminally 
Myc tagged, C-terminally fused to GFP, and expressed in MCF-7 
breast carcinoma cells, which were examined by confocal la-
ser scanning microscopy (CLSM). In unstimulated cells, Myc 
and GFP signals indicated a cytoplasmic localization of full-
length Myc Bid GFP (Fig. 1 A, I–III). After stimulation with 
TNF-α for 8 h, the GFP signal was punctate and colocalized 
with MitoTracker, which indicates translocation of tBid-C GFP 
to mitochondria (Fig. 1 A, V and VI). Surprisingly, Myc tBid-N 
was undetectable by CLSM (Fig. 1 A, IV).
Full-length Myc Bid GFP was readily detectable by both 
anti-Myc and -GFP immunoblotting in unstimulated MCF-7 cells 
and gradually decreased after stimulation with TNF-α (Fig. 1 B). 
Although the tBid-C GFP fragment could readily be visual-
ized at the 4- and 8-h time points, the Myc tBid-N fragment 
(predicted molecular mass, 7 kD) was undetectable (Fig. 1 B). 
Similar results were obtained with an antibody that recognizes 
both N- and C-terminal epitopes on Bid (unpublished data). After 
stimulation with the death receptor ligand TRAIL, a similar pic-
ture emerged. At the 8-h time point, full-length Myc Bid GFP 
levels were decreased and a tBid-C GFP fragment had been 
generated. However, no Myc tBid-N was detectable (Fig. 1 C). 
Collectively, these results suggest that the tBid-N fragment that 
is generated by caspase-8/10 is rapidly degraded.
tBid-N is degraded in a proteasome-
dependent manner
To investigate whether tBid-N was degraded by the proteasome, 
MCF-7 cells were stimulated with TNF-α in the presence or 
absence of the proteasome inhibitor MG132. Stimulation with 
TNF-α for 8 h resulted in the appearance of the endogenous 
tBid-C fragment but the tBid-N fragment was barely detectable 
(Fig. 2 A, left). When cells were stimulated in the presence of 
MG132, the amount of endogenous tBid-N was clearly increased. 
Similar results were obtained with transfected Myc Bid GFP; the 
Myc tBid-N fragment was only detectable when cells were stimu-
lated in the presence of MG132 (Fig. 2 A, right).
To determine whether targeting of tBid-N for proteasomal 
degradation required a proapoptotic stimulus, the tBid-N fragment 
was expressed in cells. The degradation pathway was constitu-
tively active because protein synthesis inhibition with cyclohex-
imide (CHX) for 8 h resulted in the loss of HA-tagged tBid-N 
(Fig. 2 B). Proteasome inhibition with MG132 abrogated this 
loss and increased the HA tBid-N pool in cells that had not been 
treated with CHX (Fig. 2 B). HA tBid-N–expressing cells were 
pulse labeled for 2 h with [
35S]methionine and [
35S]cysteine and 
the fate of the labeled pool was followed during a 60-min chase 
period. The half-life of the labeled HA tBid-N pool was  5 min 
(Fig. 2 C). Untagged tBid-N was even more unstable than the 
HA-tagged version; it was only detectable when cells had been 
incubated with MG132 (Fig. 2 D). Collectively, these results in-
dicate that tBid-N, upon its generation by caspase-8/10, is tar-
geted for proteasome-dependent degradation by a pathway that 
is not dependent on apoptotic stimulation.
tBid-N is ubiquitinated in an unconventional 
manner
Because tBid-N was targeted to the proteasome, we investigated 
whether it was ubiquitinated. To this end, tBid-N N-terminally 
tagged with the HA epitope (sequence YPYDVPDYA) was ex-
pressed in HeLa cells with or without FLAG-tagged ubiquitin. 
An anti-HA reactive smear, characteristic of polyubiquitination, 
was associated with immunoprecipitated HA tBid-N (Fig. 3 A). 
In addition, we examined ubiquitination of tBid-N as generated 
from full-length Bid after death receptor stimulation. MCF-7 
cells expressing Myc Bid GFP were left untreated or stimulated 
with TNF-α for 8 h in the presence of MG132. Lysates were 
immunoprecipitated with anti-GFP and immunoprecipitated se-
quentially with an anti-Myc antibody to recover a Myc tBid-N 
fragment. Immunoblotting for Bid and ubiquitin revealed that UNCONVENTIONAL UBIQUITINATION ALLOWS BID ACTIVITY • TAIT ET AL. 1455
ubiquitin was uniquely associated with cleaved but not full-
length Bid and specifi  ed that Myc tBid-N contained ubiqui-
tin (Fig. 3 B). Ubiquitin was also found to be associated with 
tBid-C in accordance with previously published data (Breitschopf 
et al., 2000b).
Ubiquitination was surprising because tBid-N has no ly-
sine residues that conventionally act as ubiquitin acceptor sites 
(Fig. S1 B). Typically, ubiquitin can be linked either via a peptide 
bond to the ε amino group of a lysine residue or to the α amino 
group of an N-terminal residue (Ciechanover and Ben-Saadon, 
2004). Because linkage to lysine was excluded, we investigated 
whether the N terminus of tBid-N acted as a ubiquitin acceptor 
site. To this end, tBid-N was fused C-terminally to a tandem af-
fi  nity purifi  cation (TAP) tag, which contains a calmodulin-binding 
domain and protein A sequence separated by a tobacco etch 
virus (TEV) protease-sensitive site (ENLYFQG). This allows for 
Figure 1.  tBid-N disappears upon its generation. (A) MCF-7 
cells expressing Myc Bid GFP were stimulated with TNF-α for 
8 h or not (control), stained to detect mitochondria (MitoTracker) 
and the N-terminal Myc tag, and examined by CLSM. (B and C) 
MCF-7 cells expressing Myc Bid GFP were stimulated with 
TNF-α or TRAIL. Equal amounts of total lysate protein were 
separated by SDS-PAGE, blotted to nitrocellulose, probed 
with antibodies to the N-terminal Myc and C-terminal GFP tags, 
and reprobed with an anti-actin antibody as a loading con-
trol. Molecular masses (kD) of marker proteins are indicated.JCB • VOLUME 179 • NUMBER 7 • 2007  1456
two-step purifi  cation; fi  rst on IgG beads and then after cleavage 
by TEV on calmodulin beads (Rigaut et al., 1999). In one tBid-N 
TAP construct (TEV tBid-N TAP 7), sequences encoding the 
fi  rst seven amino acids of tBid-N and a TEV protease site were 
cloned upstream of the tBid-N coding region (Fig. 3 C). If tBid-N 
would indeed be ubiquitinated at its N-terminal residue, TEV 
cleavage should remove the associated ubiquitin. tBid-N TAP 
and TEV tBid-N TAP 7 were expressed with HA-ubiquitin 
in HeLa cells. Fig. 3 C (I) shows the position of tBid-N TAP 
proteins before TEV cleavage, as isolated with IgG beads. TEV 
cleavage was successful, as shown by the difference in migra-
tion of Bid species recovered on calmodulin beads (Fig. 3 C, II). 
After TEV cleavage, ubiquitin remained attached to digestion 
product of TEV tBid-N TAP 7 (Fig. 3 C, III). TEV protease had 
effi  ciently cleaved at the N-terminal site because the difference 
in molecular mass between the two Bid species was smaller than 
before TEV cleavage (Fig. 3 C, compare I and II). A very small 
difference remained because TEV cleaves within the added 
protease recognition sequence. Ubiquitin was attached to Bid 
and not to the TAP tag because the TAP tag alone did not carry 
ubiquitin upon coexpression with HA-ubiquitin in HeLa cells 
(Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb
.200707063/DC1). This experiment argues against the possibility 
that the N-terminal residue of tBid-N is the ubiquitin acceptor 
site. Moreover, analysis of the fi  rst tryptic peptide of tBid-N 
TAP by MALDI-TOF/TOF mass spectrometry determined that 
the N terminus of Bid is acetylated and thereby not available for 
ubiquitin modifi  cation (unpublished data). These data indicate 
that tBid-N is ubiquitinated at a site that is neither a lysine nor 
the N terminus.
Helix 1 in Bid is critical for ubiquitination
To identify regions in tBid-N that were required for ubiquitina-
tion and concomitant proteasome-mediated degradation, we made 
progressive N-terminal deletions. Deletion mutants of tBid-N 
GFP were expressed in HeLa cells, which were treated or not 
Figure 2.  tBid-N is degraded by the proteasome. (A) MCF-7 
cells that were not transfected (left) or transfected with Myc 
Bid GFP (right) were stimulated with TNF-α alone or in combi-
nation with MG132 for 8 h. Total lysates were probed for 
endogenous Bid (left) or transfected Myc Bid GFP (right) and 
cleavage fragments thereof with an anti-Bid antibody. Reprobing 
was performed with an anti-Myc antibody. (B) HeLa cells ex-
pressing HA-tagged tBid-N were treated for 8 h with CHX 
and the proteasome inhibitor MG132 as indicated. Total cell 
lysates were probed for HA tBid-N with an anti-HA antibody. 
(C) HeLa cells expressing HA tBid-N were labeled with 
[
35S]methionine and [
35S]cysteine for 2 h followed by a chase 
with nonradioactive amino acids for the indicated time periods. 
Bid protein was immunoprecipitated (IP) from detergent 
lysates with anti-HA mAb and resolved by SDS-PAGE. Radio-
active signals were quantiﬁ  ed by phosphorimaging. IDV, inte-
grated density value. (D) HeLa cells transfected to express 
untagged tBid-N were treated or not with MG132 for 16 h. 
Total lysates were probed for tBid-N with an anti-Bid antibody. 
Blots were reprobed with an anti-actin antibody as indicated. 
Molecular masses (kD) of marker proteins are indicated.UNCONVENTIONAL UBIQUITINATION ALLOWS BID ACTIVITY • TAIT ET AL. 1457
with CHX for 8 h and stability was assessed by immunoblott-
ing of total cell lysates. Although tBid-N GFP remained highly 
unstable upon deletion of up to 13 N-terminal residues, deletion 
of 15 or more (17, 23, or 33) N-terminal amino acids dramati-
cally increased its half-life (Fig. 4 A). To assess whether stabili-
zation correlated with decreased ubiquitination, wild-type and 
∆15 tBid-N GFP were expressed in HeLa cells together with 
FLAG-tagged ubiquitin. Anti-Bid immunoblotting of total cell 
lysates showed that wild-type and ∆15 tBid-N GFP were ex-
pressed to a similar extent (Fig. 4 B). Ubiquitinated tBid-N GFP 
species were immunoprecipitated with an anti-FLAG antibody 
and identifi  ed by anti-Bid immunoblotting. This analysis showed 
that wild-type tBid-N GFP was polyubiquitinated, whereas the 
∆15 tBid-N GFP mutant bore virtually no ubiquitin (Fig. 4 B). 
FLAG ubiquitin expression was comparable in all transfectants 
(unpublished data). The combined fi  ndings in the stability and 
Figure 3.  tBid-N is ubiquitinated in an unconventional manner. (A) HeLa cells were transfected to express HA tBid-N alone or in combination with FLAG-
tagged ubiquitin. HA tBid-N was immunoprecipitated and probed with an anti-HA mAb to detect Bid and probed with anti-FLAG mAb to detect ubiquitin. 
Asterisks indicate heavy and light chains of anti-HA mAb. (B) MCF-7 cells expressing Myc Bid GFP were stimulated with TNF-α in the presence of MG132 
for 8 h or not stimulated (control). Lysates were immunoprecipitated with an anti-GFP antibody and immunoprecipitated sequentially (seq) with an anti-Myc 
mAb, and immunoprecipitates (IP) were probed with an anti-Bid antibody and a P4D1 anti-ubiquitin mAb. (C) Assay to determine whether the N terminus 
is ubiquitinated. In the diagram, the tBid-N TAP proteins are assessed for ubiquitination. Cal–TEV–Prot A indicates the TAP tag with calmodulin- and 
IgG-binding sites separated by a cleavage site for TEV protease (arrows). HeLa cells were transfected to express HA-ubiquitin and TAP-tagged tBid-N. 
TAP-tagged tBid-N proteins were isolated with IgG beads, digested with TEV protease, and reisolated with calmodulin beads. Isolates were probed for ubiquitin 
with an anti-HA mAb and for tBid-N with an anti-Bid antibody. Note that in I, the Prot A sequence is still attached to the tBid-N TAP species and the anti-Bid 
antibody binds to it. Molecular masses (kD) of marker proteins are indicated.JCB • VOLUME 179 • NUMBER 7 • 2007  1458
Figure 4.  Helix 1 is critical for tBid-N ubiquitination and degradation. (A) Wild-type (wt) tBid-N GFP and deletion (∆) mutants lacking 7, 13, 15, 17, 23, 
or 33 N-terminal amino acids were expressed in HeLa cells, which were treated (+) or not (−) with CHX for 8 h. The tBid-N GFP proteins were detected 
in total lysates by immunoblotting with anti-Bid antibody. (B) GFP, wt, and ∆15 tBid-N GFP were expressed in HeLa cells together with FLAG-tagged ubiquitin. 
Total cell lysates (TCL) were probed with an anti-Bid antibody to assess tBid-N expression levels. Ubiquitinated protein species were isolated with an 
anti-FLAG mAb (IP) and probed with an anti-Bid antibody. Single asterisk indicates heavy and light chains of the anti-FLAG mAb; double asterisk indicates 
endogenous full-length Bid. (C) FLAG-tagged ubiquitin was coexpressed in HeLa cells with HA tBid-N versions with a TEV protease cleavage site at position 
10, 30, or 43. HA tBid-N molecules were isolated, incubated with (+) or without (−) TEV protease, run on a gel, and probed by immunoblotting for Bid 
and ubiquitin (anti-FLAG). In the case of HA tBid-N TEV 10, the HA-tagged cleavage fragment repeatedly did not resolve on gel but the remaining un-
digested HA tBid-N TEV 10 and weakly ubiquitinated species of the cleavage fragment (arrows) are clearly visible. All experiments in this ﬁ  gure were per-
formed three times with similar results. Molecular masses (kD) of marker proteins are indicated.UNCONVENTIONAL UBIQUITINATION ALLOWS BID ACTIVITY • TAIT ET AL. 1459
ubiquitination assays lead to the conclusion that residues 14 
and/or 15 contain information that is critical for ubiquitination 
and destabilization of tBid-N. These are the fi  rst residues that 
take part in the α helix 1 of Bid (Fig. S1 B). Their deletion is ex-
pected to disrupt this structure and may therefore result in the 
loss of ubiquitination sites and/or the loss of a binding site for 
the ubiquitin ligase.
To ascertain whether helix 1 contained ubiquitination sites, 
we performed mapping experiments. Cleavage sites for the TEV 
protease were introduced in HA tBid-N after residues 10, 14, 
30, or 43 and these recombinant proteins were   expressed in the 
presence of FLAG ubiquitin. They were isolated with anti-HA 
antibody, digested with TEV protease, and probed for the pres-
ence of ubiquitin and Bid. In the case of the HA tBid-N TEV 43 
and 30 proteins, cleavage with TEV protease resulted in a shift 
in molecular mass of both Bid and the ubiquitin signal. There 
was no apparent loss of the ubiquitin signal (Fig. 4 C). This 
proves that tBid-N is directly ubiquitinated and indicates that 
predominant ubiquitin acceptor sites are among residues 1–30 of 
tBid-N. The HA tBid-N TEV 14 protein did not cleave with TEV 
protease (unpublished data). Upon TEV digestion of HA tBid-N 
TEV 10, the ubiquitin signal was strongly reduced (Fig. 4 C). 
Figure 5.  Ubiquitin is partially reducible, hydrolyzable, and affected by combined mutation of S, T, and C residues. (A) HA tBid-N was coexpressed with 
FLAG ubiquitin in HeLa cells. Anti-HA immunoprecipitates were reduced (+) or not (−) as described in Materials and methods and reprecipitated with an 
anti-HA mAb. Reprecipitates were probed for Bid (anti-HA) and ubiquitin (anti-FLAG). Recombinant E2-25K as a positive control for cysteine ubiquitination 
was ubiquitinated in vitro, reduced or not, and probed with mAb to E2-25K or ubiquitin. The asterisk indicates free recombinant ubiquitin. IDV, integrated 
density values showing comparable tBid-N loading. (B) Alanine substitution mutations were generated in HA tBid-N TEV 30. All mutants listed in Table S1 
(available at http://www.jcb.org/cgi/content/full/jcb.200707063/DC1) were tested for ubiquitination and part of the results are shown here. Wild-type 
and mutant proteins were expressed in HeLa cells together with FLAG ubiquitin, isolated with anti-HA mAb, and treated (+) or not (−) with TEV protease. 
Anti-HA immunoblotting was performed to assess Bid expression and cleavage and anti-FLAG immunoblotting was performed to examine ubiquitination. 
Arrows indicate positions of the ubiquitinated TEV cleavage fragment. (C) tBid-N TAP was coexpressed with HA-ubiquitin in HeLa cells. Cell lysates were 
treated at pH 7.4 or 12 as indicated in Materials and methods and tBid-N TAP was puriﬁ  ed on the TAP tag. Calmodulin-bound protein was separated by 
SDS-PAGE and probed for Bid (anti-Bid) and ubiquitin (anti-HA). All experiments in this ﬁ  gure were performed three times with similar results. Molecular 
masses (kD) of marker proteins are indicated. Black lines indicate that intervening lanes have been spliced out. JCB • VOLUME 179 • NUMBER 7 • 2007  1460
The HA tBid-N 1–10 fragment did not resolve on a gel, but weakly 
ubiquitinated species of this fragment are visible (Fig. 4 C, arrows). 
The remaining ubiquitin was mainly associated with the undi-
gested HA tBid-N TEV 10. We conclude that tBid-N is pre-
dominantly ubiquitinated on sites between residues 10 and 30 
but also to a certain extent on sites between residues 1 and 10. 
The deletion and mapping experiments collectively indicate 
that helix 1 (residues 14–29; Fig. S1 B) is critical for ubiquitina-
tion to occur.
tBid-N is likely ubiquitinated on cysteine, 
serine, and/or threonine residues
Lack of lysine residues is a common feature of tBid-N in different 
species (human, chimpanzee, mouse, rat, cow, and pig; Fig. S1 C). 
We surmised that tBid-N might be ubiquitinated on cysteine 
residues. Three such sites are available among residues 1–30 of 
human tBid-N: C3, C15, and C28. Ubiquitin linkage to cysteine is 
not uncommon because the E2 and E3 enzymes are charged with 
ubiquitin in this manner. In such case, the carboxyl group of the 
C-terminal glycine in ubiquitin forms a thioester bond with the 
sulfhydryl group in cysteine, which is easily reducible. To ad-
dress this possibility, ubiquitinated HA tBid-N was isolated and 
subjected to reduction with DTT under denaturing conditions. 
HA tBid-N was reprecipitated with an anti-HA antibody to separate 
it from possibly dissociated ubiquitin moieties. As a positive con-
trol, we used in vitro–ubiquitinated E2-25K, an E2 that is mono-
ubiquitin charged through a thioester bond in its active site (Pichler 
et al., 2005). Indeed, DTT treatment resulted in a loss of ubiquitin 
from E2-25K species (Fig. 5 A). Importantly, the same treatment 
diminished the amount of ubiquitin appended to HA tBid-N 
(Fig. 5 A). This experiment indicates that cysteines are among the 
ubiquitin acceptor sites in tBid-N. However, we found with high 
reproducibility that ubiquitin was partially retained on tBid-N 
upon reduction, which argues that other residues play roles as ac-
ceptor sites as well. Point mutation of C15 or C28 either alone or 
in conjunction (Table S1, available at http://www.jcb.org/cgi/
content/full/jcb.200707063/DC1) did not stabilize tBid-N (Fig. S3). 
It also did not reproducibly reduce ubiquitination of the 1–30 
fragment of HA tBid-N TEV 30 (Fig. 5 B). Additional mutation 
of C3 made HA tBid-N TEV 30 very unstable, such that it could 
only be expressed at lower levels than the wild-type protein (Figs. 
5 B and S3). However, it could clearly be demonstrated that the 
cysteine-defi  cient (C3;C15;C28) mutant of HA tBid-N TEV 30 
still carried ubiquitin after TEV digestion (Fig. 5 B). This relates 
with the partial reducibility of ubiquitination and leads to the im-
portant conclusion that residues 1–30 of tBid-N harbor residues, 
other than cysteine, to which ubiquitin can be conjugated.
The potential alternative ubiquitination sites in tBid-N 
(1–30) are serine and threonine residues because the carboxyl 
group of the C-terminal glycine in ubiquitin can theoretically 
form an ester bond with the hydroxyl group in the side chain of 
these amino acids. There is recent biological precedent for this 
type of ubiquitin conjugation by viral ubiquitin ligases (Wang 
et al., 2007). To test this possibility, we investigated whether the 
ubiquitin linkage was susceptible to alkaline hydrolysis. HeLa 
cells expressing tBid-N TAP and HA-ubiquitin were lysed at 
either pH 7.4 or 12, heated for 10 min at 70°C, diluted in buffer 
with neutral pH, and subjected to TAP purifi  cation. Isolates were 
probed for Bid and ubiquitin. Equal amounts of tBid-N TAP 
were recovered from both lysates but, after treatment at pH 12, 
the amount of ubiquitin associated with tBid-N was greatly 
diminished (Fig. 5 C). Thioester bonds are very easily hydro-
lysable but the dramatic loss of ubiquitination after hydrolysis 
was compatible with the notion that hydroxyl ester bonds were 
involved as well. To verify that the hydrolysis procedure left 
conventional lysine-linked ubiquitin moieties unaffected, we 
tested its effect on a complex of purifi  ed, in vitro–ubiquitinated 
Ring1b and Bmi1 (Buchwald et al., 2006). After the ubiquitina-
tion reaction, the complex was incubated at pH 7.4 or 12, exactly 
as was done for tBid-N TAP. In addition, it was heated in the 
presence of β-mercaptoethanol to test the effect of reduction. 
The conditions were neutralized and the complex was recovered 
by virtue of His tags and examined for the extent of ubiquitina-
tion by immunoblotting. None of the treatments affected the 
ubiquitination status of Ring1b (Fig. S4, available at http://www
.jcb.org/cgi/content/full/jcb.200707063/DC1).
For mutation analysis of serines and threonines, we focused 
on the residues in helix 1. Among these, T17 is completely con-
served between species (Fig. S1 C). However, alanine substitu-
tion of T17 alone did not stabilize tBid-N or affect ubiquitination 
of the 1–30 fragment of tBid-N (unpublished data). Additional 
mutation of S27, C28, and S29 or mutation of all serines, threo-
nines, and cysteines in helix 1 did not stabilize tBid-N either 
(Fig. S3). It reproducibly reduced ubiquitination of the 1–30 
fragment to a certain extent but did not abrogate it (Fig. 5 B). 
Additional mutation of C3 rendered HA tBid-N TEV 30 highly 
unstable (Fig. S3), but we could reveal ubiquitination on the 
1–30 fragment, which supports the conclusion that residues other 
than cysteines are acceptor sites (Fig. 5 B). This result indicated 
a possible role for S9 and/or S10. However, alanine substitution 
of these residues either alone or in conjunction with the poten-
tial acceptor sites in helix 1 did not stabilize tBid-N (Fig. S3). 
Importantly, ubiquitination of the 1–30 fragment was virtually 
abrogated when alanine substitution of S9 and S10 was com-
bined with alanine substitution of cysteine, threonine, and ser-
ine residues in helix 1 (Fig. 5 B). This result indicates that one 
or more of these residues is a ubiquitination site.
We conclude from the combined biochemical and mutation 
analyses that tBid-N is ubiquitinated on cysteine residues, but 
not exclusively so. There are ubiquitination sites other than cys-
teine among residues 1–30. We postulate that these are serine 
and/or threonine residues, given the hydrolysability of the ubiq-
uitination and the results of mutation analysis. Unambiguously 
pinpointing the ubiquitination sites by mutation analysis is ham-
pered by the effects of mutation on protein stability and by the fact 
that the ubiquitination machinery is promiscuous and ubiquitinates 
multiple sites, including alternative residues when the primary 
target sites are not available because of mutation.
Proteasome-dependent degradation of 
tBid-N is critical for its membrane-
permeabilizing activity of tBid-C
To investigate whether degradation of tBid-N was required 
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  inhibition on tBid-C translocation. MCF-7 cells expressing Myc 
Bid GFP were stimulated with TNF-α for 8 h in the presence or 
absence of MG132 and examined by CLSM for the distribution of 
Myc tBid-N and tBid-C GFP cleavage fragments. In accordance 
with the biochemical data (Fig. 2 A), Myc tBid-N was rescued 
from degradation by MG132 (Fig. 6 A, IV). Despite this, tBid-C 
GFP translocated to mitochondria (Fig. 6 A, V), where it partially 
colocalized with Myc tBid-N (VI). This result indicates that the 
degradation of tBid-N is not required for tBid-C translocation. 
In line with a previous study (Zha et al., 2000), it also suggests 
that the cleaved but still associated tBid-N–tBid-C complex can 
translocate to mitochondria. Next, we investigated whether prote-
asome inhibition affected the capacity of tBid-C to permeabilize 
the mitochondrial outer membrane. Untransfected MCF-7 cells 
were stimulated with TNF-α in the presence or absence of MG132 
and analyzed by fl  ow cytometry for Cyt c content. The dramatic 
release of Cyt c induced by TNF-α stimulation was greatly re-
duced upon coincubation with MG132 (Fig. 6 B), which suggests 
that degradation of tBid-N is required for tBid-C function.
Because the proteasome may have other targets in this 
pathway, we aimed to test a Bid molecule harboring tBid-N that 
could escape from proteosomal degradation. Unfortunately, the 
stabilizing N-terminal deletion mutation ∆15 unleashed consti-
tutive mitochondrial localization and permeabilizing activity in 
full-length Bid (unpublished data) and was therefore not useful. 
In the course of our study, however, we had noted that the addi-
tion of a bulky group such as GFP or a repetitive Myc tag to the 
N terminus of tBid-N greatly increased its stability. Therefore, 
we compared the functional activity of GFP Bid with a vesicu-
lar stomatitis virus (VSV) tag, which contains a stabilized GFP 
tBid-N, with that of Myc Bid GFP, which contains the wild-type, 
unstable Myc tBid-N.
To create a cell line that exclusively expressed stabilized 
tBid-N, endogenous Bid was constitutively down-regulated in 
MCF-7 cells by RNAi (Fig. 7 A). To express stabilized GFP Bid 
VSV and control (unstable) Myc Bid GFP in these cells, a silent 
mutation was introduced into the Bid sequence that was not tar-
geted by the siRNA. This allowed appropriate expression of the 
Figure 6.  Proteasome inhibition prohibits 
tBid-C function. (A) MCF-7 cells expressing Myc 
Bid GFP were stimulated with TNF-α with or 
without MG132 for 8 h. Stimulation resulted 
in translocation of tBid-C GFP (green) to mito-
chondria (II and III). In the presence of MG132, 
Myc tBid-N (red) remained detectable (IV), which 
indicates escape from proteasomal degradation. 
N- and C-terminal epitopes partially colocalized 
at mitochondria (VI). (B) TNF-α–induced Cyt c 
release in the presence or absence of MG132 
was tested by ﬂ   ow cytometric analysis in un-
transfected MCF-7 cells after 8 h of stimulation. 
Results are means + SD from three independ-
ent experiments. The asterisk indicates a statis-
tically signiﬁ  cant difference (P < 0.05 according 
to a t test). C, control.JCB • VOLUME 179 • NUMBER 7 • 2007  1462
Bid constructs upon transient transfection (Fig. 7, A and B). The pro-
cessing of Myc Bid GFP and GFP Bid VSV by caspase-8/10 
and the half-life of the Bid fragments were followed kinetically 
after stimulation of the reconstituted MCF-7 cells with TNF-α. 
In the case of Myc Bid GFP, the tBid-C GFP cleavage product 
was visible from the 2-h time point onward and its signal in-
creased in time. The Myc tBid-N fragment was detected at the 
2- and 4-h time points but not at the 8-h time point (Fig. 7 B). 
Processing of GFP Bid VSV was also visible at 2 h, but in this 
case not only the tBid-C VSV fragment remained detectable in 
the 8-h time frame but also the GFP tBid-N fragment (Fig. 7 B). 
We conclude that the GFP Bid VSV protein is properly processed 
by caspase-8/10 and that the GFP tBid-N fragment is long-lived, 
whereas the Myc tBid-N fragment has a short half-life.
The fate of stabilized GFP tBid-N was also followed by 
CLSM. In unstimulated cells, GFP and VSV signals were consis-
tent with a cytoplasmic localization of full-length GFP Bid VSV 
(Fig. 7 C, I and II). At 8 h after stimulation, the VSV signal was 
punctate and colocalized with MitoTracker, which indicates mito-
chondrial localization of tBid-C VSV (Fig. 7 C, V). The GFP 
signal was still present at this time point (Fig. 7 C, IV) and was 
partially colocalized with VSV and MitoTracker signals (VI). 
This indicated long-term stabilization of GFP tBid-N (compare 
with the disappearance of Myc tBid-N; Fig. 1 A). As in the case 
of proteasome inhibition (Fig. 6 A), tBid-N stabilization did not 
interfere with mitochondrial translocation of tBid-C and both 
fragments partially colocalized at the mitochondria. This suggests 
that tBid-N and tBid-C may remain associated after cleavage of 
full-length Bid and translocate to mitochondria as a complex.
Next, Cyt c release upon TNF-α stimulation was compared 
in wild-type MCF-7 and Bid RNAi cells before and after re-
constitution with unstable or stabilized Bid versions. Bid RNAi 
effectively blocked TNF-α–induced Cyt c release (Fig. 7 D). 
Importantly, introduction of GFP Bid VSV bearing stabilized 
tBid-N did not restore the ability of TNF-α to induce Cyt c release, 
whereas introduction of Myc Bid GFP bearing unstable tBid-N 
did (Fig. 7 D). Collectively, these results indicate that degradation 
of tBid-N regulates the proapoptotic function of tBid-C. Based on 
these data, we propose a model in which selective removal of 
tBid-N by proteasome-mediated degradation liberates tBid-C to 
induce mitochondrial membrane permeabilization.
Discussion
Sequences in Bid’s N-terminal fragment sequester the proapop-
totic BH3 domain. Through this autoinhibitory mechanism, full-
length Bid is kept in an inactive state (Chou et al., 1999; Tan 
et al., 1999). Bid can be converted to its active form by cleavage in 
its second unstructured loop, such as at D60 by caspase-8/10 
and at D75 by granzyme B (Li et al., 1998; Luo et al., 1998; 
Sutton et al., 2003). Mechanistically, it was unclear why cleav-
age should lead to Bid activation. Upon Bid cleavage in vitro, 
the N- and C-terminal fragments remain associated according to 
both NMR and biochemical analyses (Chou et al., 1999; Zha 
et al., 2000; Kuwana et al., 2002). Moreover, several investigators 
have demonstrated that the tBid-N fragment, when expressed 
independently, can block the proapoptotic activity of the tBid-C 
fragment (Tan et al., 1999; Kudla et al., 2000; Renshaw et al., 
2004). Collectively, these data suggest a critical inhibitory effect 
of the Bid N terminus upon the C-terminal proapoptotic func-
tion both before and after Bid cleavage. Based on our results, we 
propose that cleavage of Bid acts as a proapoptotic activation 
signal by allowing ubiquitination and subsequent proteasomal 
destruction of the inhibitory N-terminal fragment.
Although originally recognized as a signal for the steady-
state destruction of aged and misfolded proteins, ubiquitination 
is now known to play an essential regulatory role in cellular sig-
naling. Various apoptosis signaling molecules are regulated by 
proteasomal destruction (Weissman, 2001; Jesenberger and 
Jentsch, 2002; Chen, 2005). These include inhibitory Bcl-2 
family members Bcl-2 (Breitschopf et al., 2000a), Mcl-1 (Liu et al., 
2005; Zhong et al., 2005), and Bfl  -1 (Kucharczak et al., 2005); 
proapoptotic Bax (Li and Dou, 2000); BH3-only proteins Bim 
(Akiyama et al., 2003; Ley et al., 2003) and Bik (Marshansky et al., 
2001); and the C-terminal fragment of Bid (Breitschopf et al., 
2000b). Polyubiquitination and degradation generally nega-
tively regulate the function of the target protein by its complete 
elimination. The case of tBid-N ubiquitination is different be-
cause it represents a form of positive regulation; it is required 
for the proapoptotic function of Bid. In the noncanonical nu-
clear factor κB pathway, polyubiquitination and partial protein 
degradation of p105/p100 also acts as an activating principle 
(Chen, 2005). In both the case of the nuclear factor κB precur-
sor and Bid, a portion of the molecule escapes from degradation 
and is released to perform its function.
Mutation analysis specifi  cally implicated 5 out of 13 lysines 
in Mcl-1 in its destruction (Zhong et al., 2005), whereas muta-
tion of all 4 lysine residues in tBid-C was shown to increase its 
half-life (Breitschopf et al., 2000b). In the case of the other Bcl-2 
family members, no specifi  c target sites have been identifi  ed. In 
the case of Bid, ubiquitination occurred with certainty on the 
Bid fragment encompassing residues 1–30. Indeed, the TEV 
protease mapping experiments indicate that tBid-N can be ubiq-
uitinated on sites among amino acids 11–30 as well as to a lesser 
extent on sites among amino acids 1–10. This classifi  es the 
ubiquitination as unconventional because it did not concern a 
peptide bond to an ε amino group of lysine or an α amino group 
at the N terminus of the Bid protein. After reduction, ubiquitination 
was partially but not completely lost. This indicates that cys-
teine residues are among the ubiquitin acceptor sites. A thioester 
linkage is not unusual for ubiquitin because the ubiquitin conju-
gating (E2) and ubiquitin ligase (E3) enzymes bear ubiquitin in 
such a manner. However, to our knowledge, cysteine ubiquitina-
tion of a target other than E2 or E3 proteins has only one precedent 
in the existing literature. This concerns the cytoplasmic tail of 
major histocompatibility complex class I that contains no lysine 
residues but was ubiquitinated in a reducible manner by an E3 
encoded by a herpes virus (Cadwell and Coscoy, 2005). Ubiqui-
tination of tBid-N was to a signifi  cant degree maintained upon 
reduction (Fig. 5 B), which is consistent with the possibility that 
threonine and serine residues are primary targets of the ubiqui-
tination machinery. The fact that a tBid-N mutant lacking all 
three cysteine residues was still ubiquitinated on fragment 1–30 
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Figure 7.  Stabilization of tBid-N prohibits tBid-C function. (A) MCF-7 cells were depleted of endogenous Bid by stable expression of a Bid siRNA. MCF-7 Bid 
RNAi cells were reconstituted by transient transfection with Myc Bid GFP or GFP Bid VSV with silent mutations to allow escape from RNAi. The results for 
reconstitution with Myc Bid GFP wild-type and RNAi escape mutants are shown by immunoblotting for GFP in total cell lysates. Molecular masses (kD) 
of marker proteins are indicated. (B) Myc Bid GFP and GFP Bid VSV were expressed in MCF-7 Bid RNAi cells and cells were stimulated for the indicated 
time periods with TNF-α. Full-length Bid and cleavage fragments were detected by anti-Bid immunoblotting of total cell lysates. Fragments were identiﬁ  ed 
additionally by immunoblotting with antibodies to Myc, GFP, and VSV (not depicted). ECL signals originate from the same blotted gel but the bottom panel 
represents a longer exposure than the top to allow detection of Myc tBid-N. (C) MCF-7 cells expressing GFP Bid VSV were stimulated with TNF-α for 8 h or 
left untreated (control). Signals diagnostic for stabilized GFP tBid-N are shown individually and in combination with the signals for tBid-C (VSV) and 
MitoTracker. The enlarged views allow assessment of colocalization of tBid-N and tBid-C at mitochondria. (D) TNF-α–induced Cyt c release was tested after 
8 h of stimulation by ﬂ  ow cytometric analysis in parental MCF-7 cells, cells lacking Bid (MCF-7 Bid RNAi), and the same cells reconstituted with either Myc 
Bid GFP (unstable tBid-N) or GFP Bid VSV (stabilized GFP tBid-N). MCF-7 and MCF-7 Bid RNAi cells were additionally transfected to express histone-GFP. 
Cyt c content was monitored in cells gated for equal GFP expression to standardize for transfected Bid levels. Results are means + SD from three independ-
ent experiments. Values are corrected for Cyt c release in the absence of stimulus (15 ± 5%). The asterisk indicates statistically signiﬁ  cant difference 
(P < 0.05 according to a t test).JCB • VOLUME 179 • NUMBER 7 • 2007  1464
This is consistent with the fact that cysteines are not fully con-
served in tBid-N. In fact, rat tBid-N does not contain any cys-
teines (Fig. S1 C).
Our extensive mutational analysis has not pinpointed the 
ubiquitination sites. These experiments are hampered by the fact 
that ubiquitin is likely appended to other candidate sites when 
the original sites are not available, including residues outside 
region 1–30. Mutation of all cysteines, threonines, and serines in 
tBid-N made it much more unstable than the wild-type protein, 
such that it was barely detectable even in the presence of protea-
some inhibitor (unpublished data). In this case, the protein likely 
bears little structural resemblance to the wild-type tBid-N and 
results are diffi  cult to interpret. Thus far, attempts to map the 
ubiquitination sites by mass spectrometry have not been suc-
cessful. Lability of the thioester bonds is the most likely limiting 
factor in this analysis, particularly after tryptic digestion, which 
converts the polyubiquitin chain into a reactive Gly Gly amine. 
Theoretically, ubiquitin can link to serine and threonine by the 
formation of an ester bond between the carboxyl group of the 
C-terminal glycine and the hydroxyl group in the side chain of 
these amino acids. The fi  rst evidence for such linkage in a bio-
logical system was being published when this manuscript was in 
the fi  nal stage of preparation. It again concerned the cytoplas-
mic tail of major histocompatibility complex class I, which was 
ubiquitinated by another herpes virus–derived E3 than the one 
responsible for cysteine ubiquitination (Wang et al., 2007). Our 
work provides additional evidence for such linkage and adds 
that it can occur in a mammalian system.
Although ∆13 tBid-N was as unstable as the wild-type ver-
sion, the ∆15 mutant was fully stabilized. C15 is a good candidate 
ubiquitin acceptor site because it lies at the border of helix 1 and 
is accessible in the Bid structure (Chou et al., 1999; McDonnell 
et al., 1999). However, point mutation of C15 did not affect ubiq-
uitination. In stark contrast, ubiquitination was almost completely 
lost from tBid-N GFP upon deletion of residues 1–15. This sug-
gests that these residues, particularly residues 14 and 15 (given 
the instability of the ∆13 mutant), are critical for binding of the 
(undefi  ned) ubiquitination machinery to tBid-N.
In our CLSM experiments, we found tBid-N together with 
tBid-C at the mitochondrial membrane after TNF-α stimulation 
when tBid-N degradation was blocked by proteasome inhibition 
(Fig. 6 A) or GFP fusion (Fig. 7 C). It is therefore clear that 
tBid-N degradation is not required for mitochondrial transloca-
tion of tBid-C. We suggest that the stabilized tBid-N fragment 
inhibits the function of tBid-C at the mitochondria. In time 
course experiments with wild-type Myc Bid GFP, we also found 
a degree of colocalization of Myc and GFP signals at mito-
chondria at 2 h after TNF-α stimulation (Fig. S5, available at 
http://www.jcb.org/cgi/content/full/jcb.200707063/DC1). These 
fi  ndings tie in with the in vitro observation that the cleaved com-
plex stays intact (Chou et al., 1999) and a previous study showing 
the association of the cleaved Bid complex with mitochondria 
(Zha et al., 2000). These data suggest that tBid-N and tBid-C may 
remain associated during mitochondrial translocation. Further 
experiments are required to resolve whether tBid-N ubiquitina-
tion takes place at the mitochondrial membrane and whether this 
event determines its dissociation from tBid-C.
We have shown here that Bid’s proapoptotic function is 
activated through cleavage-inducible ubiquitination and protea-
somal degradation of tBid-N. Freeing of the BH3 domain by this 
mechanism may apply to other Bcl-2 family members as well. 
For instance, BimEL is cleaved by caspases at an early stage 
during apoptosis induction, which renders it more proapoptotic 
(Chen and Zhou, 2004). Moreover, Bcl-2, Bfl  -1, and Bcl-xL can be 
converted into proapoptotic proteins after cleavage by caspases 
or calpain (Clem et al., 1998; Kucharczak et al., 2005). Perhaps, 
in these cases, a similar mechanism operates as we have shown 
here for Bid activation.
Materials and methods
Cells and reagents
Human cervix carcinoma line HeLa, breast carcinoma line MCF-7, and 
293 embryonic kidney cell–derived packaging line ΦNX-Ampho were 
grown in DME medium with fetal calf serum. Human TNF-α was used at 
10 ng/ml in combination with CHX at 10 μg/ml (both obtained from Sigma-
Aldrich), soluble human FLAG-tagged TRAIL in combination with an   enhancer 
(Qbiogene) at 100 ng/ml, and MG132 (EMD) at 50 μM. mAbs used were: 
anti-HA 12CA5, anti-Myc 9E10, anti-VSV P5D4 (puriﬁ  ed Ig prepared 
from available hybridomas), anti-FLAG M2 (Sigma-Aldrich), anti-actin C4 
(Chemicon), anti–Cyt c 6H2.B4 (BD Biosciences), anti-ubiquitin P4D1 
(Santa Cruz Biotechnology, Inc.). Polyclonal rabbit sera used were: anti-
Bid raised against a GST fusion protein of full-length human Bid (available 
from BD Biosciences; Werner et al., 2002), anti-GFP (Clontech Laboratories, 
Inc.), anti-E2-25K UG9520 (BIOMOL International, L.P.). HRP-conjugated 
rabbit anti–mouse Ig and pig anti–rabbit Ig were obtained from Dako, 
HRP-conjugated anti-HA and anti-FLAG mAb were obtained from Sigma-
Aldrich, and goat anti–mouse Ig conjugated to Alexa Fluor 594 was obtained 
from Invitrogen.
Plasmids
Construction of cDNA encoding full-length human Bid fused C-terminally to 
eGFP (Bid GFP) made use of vector eGFPN1 (Clontech Laboratories, Inc.). 
A construct encoding full-length Bid GFP with an N-terminal Myc tag was 
created by placing a polylinker encoding a Myc epitope 5′ in frame to the 
Bid initiation codon. cDNA encoding the tBid N-terminal residues 1–60 
(tBid-N) was cloned into eGFPN1, eGFPC1 (Clontech Laboratories, Inc.), 
pMT2SM, pMT2SM-VSV, and pMT2SM-HA (Werner et al., 2002) by 
PCR/restriction enzyme–based methods. The plasmid encoding histone 2B-GFP 
has been described previously (Tait et al., 2004). Plasmid pcDNA3.1 
encoding FLAG-tagged human ubiquitin was a gift of S. Cook (Babraham 
Institute, Cambridge, UK). Plasmid pMT2SM encoding HA-tagged human 
ubiquitin has been described previously (de Melker et al., 2001). pcDNA3.
1-TAP was made by restriction enzyme–based subcloning of the TAP tag 
from pZomeC1 (Cellzome) into pcDNA3.1. tBid-N cDNA and deletion mu-
tants were cloned into pcDNA3.1-TAP by restriction enzyme–based sub-
cloning, producing constructs that were C-terminally fused to the TAP tag 
(Rigaut et al., 1999). Where used, polylinkers encoding TEV protease rec-
ognition sequences (encoding ENLYFQG) were inserted after the appropri-
ate restriction digest. Point mutants and TEV insertion constructs were 
generated using the QuikChange site-directed mutagenesis kit according 
to the manufacturer’s instructions (Stratagene).
Western blotting, metabolic labeling, and immunoprecipitation
For immunoprecipitation, all cells (adherent and ﬂ  oating) were harvested, 
washed twice in PBS, and lysed in NP-40 buffer consisting of 50 mM Tris-
HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM PMSF, and complete 
EDTA-free protease inhibitors (Roche). Cell lysates were clariﬁ  ed by centrif-
ugation for 15 min at 13,000 g and protein content was measured by pro-
tein assay (Bio-Rad Laboratories). All SDS-PAGE analysis was done on 
precast 4–12% NuPAGE minigels according to the manufacturer’s instruc-
tions (Invitrogen). In this procedure, samples were heated for 10 min at 
70°C in reducing (100 mM DTT) sample buffer before electrophoresis. 
Equal amounts of protein per lane (20 μg) were separated by SDS-PAGE 
and transferred to nitrocellulose sheets. Immunoblotting and enhanced chemi-
luminescence were performed as described previously (Tait et al., 2004). 
For metabolic labeling, cells (10
6 cells in a 10-cm dish) were starved in 
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[
35S]methionine and [
35S]cysteine (13.25 MBq per dish; GE Healthcare) 
for 2 h in the same medium. For the chase, cells were incubated for the 
indicated time in complete DME medium and supplemented with 2.5 mM of 
unlabeled methionine and cysteine. Immunoprecipitated proteins were re-
solved by SDS-PAGE, detected by autoradiography, and quantiﬁ  ed  by 
phosphorimaging (FLA-3000 and AIDA software; Fujiﬁ  lm).
Tandem afﬁ  nity puriﬁ  cation
10
6 cells were lysed in NP-40 buffer. Lysates were clariﬁ  ed by centrifuga-
tion and incubated with rabbit IgG agarose (Sigma-Aldrich) for 2 h at 4°C. 
Agarose beads were washed in NP-40 buffer and TEV cleavage buffer (10 mM 
Tris, pH 8, 0.1% NP-40, 150 mM NaCl, 0.5 mM EDTA, and 1 mM DTT) 
and incubated with 10 U TEV protease (Invitrogen) in cleavage buffer over-
night at 4°C. Next, supernatant was diluted threefold in calmodulin-binding 
buffer (10 mM Tris-HCl, pH 8, 0.1% NP-40, 150 mM NaCl, 1 mM Mg 
acetate, 1 mM imidazole, and 2 mM CaCl2) and incubated with calmodulin 
Sepharose beads (Stratagene) at 4°C for 1 h. Calmodulin-bound proteins 
were separated by SDS-PAGE and detected by Western blotting. For alkaline 
hydrolysis experiments, cells were lysed in PBS, pH 7.4 or 12, 1% NP-40, 
and complete EDTA-free protease inhibitors. Lysates were clariﬁ  ed by cen-
trifugation, heated at 70°C for 10 min, diluted 100-fold in NP-40 buffer, 
and subjected to TAP puriﬁ  cation.
Treatment of immunoprecipitates
For TEV protease treatment, HA Bid immunoprecipitates were resuspended 
in 300 μl TEV cleavage buffer and incubated with or without 2 μl TEV prote-
ase overnight at 4°C. Beads were spun down, washed three times, and 
taken up in sample buffer for SDS-PAGE. For reduction, HA Bid immunopre-
cipitates were suspended in 10 μl NP-40 buffer. To this, 15 μl of 100 mM 
Tris-HCl, pH 6.8, 4% SDS, 8 M urea, and 20% glycerol was added with or 
without 600 mM of fresh DTT. Control samples without DTT were kept on ice, 
whereas samples with DTT were heated at 95°C for 10 min. Next, samples 
were diluted out 80 times in NP-40 buffer with 10 mM iodoacetamide and 
50 μg/ml RNase A (as carrier protein). Beads were spun down and super-
natants were subjected to reprecipitation with anti-HA antibody. For the se-
quential immunoprecipitation shown in Fig. 3 B, after immunoprecipitation 
with anti-GFP antibody, the lysate was incubated three times with protein G–
Sepharose beads followed by immunoprecipitation with anti-Myc antibody.
In vitro ubiquitination
To ubiquitinate the recombinant E2 core domain of E2-25K (Pichler et al., 
2005), recombinant human ubiquitin-activating enzyme (E1; 120 ng; 
0.2 μM), E2-25K
1-155 (1.5 μg; 17 μM), and ubiquitin (2 μg; 47 μM) 
were co  incubated in 20 mM Tris-HCl, pH 8, 100 mM NaCl, and 5 mM 
β-mercapto  ethanol with 5 mM ATP and 5 mM MgCl2 for 2 min at 23°C. 
Reactions were terminated by 1:1 dilution in sample buffer (100 mM Tris, 
pH 6.8, 8 M urea, 4% SDS, and 20% glycerol with or without 600 mM DTT) 
and samples were kept on ice or heated at 95°C as described in the previous 
paragraph before electrophoresis. A complex of His-tagged Ring1b (resi-
dues 1–331) and full-length His-tagged Bmi1 were coexpressed in Sf9 insect 
cells by simultaneous infection with separate recombinant baculoviruses. 
The complex was puriﬁ  ed on nickel-agarose (Hitrap column; GE Health-
care) and further puriﬁ  ed as described previously (Buchwald et al., 2006). 
Ring1b/Bmi1 was incubated at 6 μM together with 220 nM human E1, 
2 μM human UbcH5c, 20 μM ubiquitin, and 3 mM ATP in a total volume of 
50 μl of ligase buffer consisting of 50 mM Tris-HCl, pH 7.5, 100 mM 
NaCl, 10 mM MgCl2, 1 μM ZnCl2, and 1 mM DTT at 30°C for 1 h. For the 
control sample, the ubiquitination reaction was stopped by the addition 
of LDS sample buffer (NuPAGE; Invitrogen). Samples for immunoprecipita-
tion were: (a) incubated with 12.5-fold excess of ligase buffer as control, 
(b) heated for 8 min at 95°C in the presence of 5% β-mercaptoethanol after 
which 12.5-fold excess ligase buffer was added, (c) incubated with 12.5-
fold excess PBS, pH 7.4, and heated for 10 min at 70°C, and (d) incu-
bated with 12.5-fold excess PBS, pH 12, and heated for 10 min at 70°C. 
Next, samples were diluted with NP-40 buffer (as described in the previous 
paragraph) to a total volume of 10 ml and subjected to immunoprecipita-
tion with nickel-agarose beads (QIAGEN). Reaction products were sepa-
rated by NuPAGE in 4–12% Bis-Tris precast gels (Invitrogen) blotted to 
nitrocellulose and probed independently with a P4D1 antibody directed to 
ubiquitin and anti-Ring1b (provided by H. Koseki, Institute of Physical and 
Chemical Research, Yokohama, Japan).
RNAi
A short interfering oligonucleotide targeting human Bid (nt 238–256, 
5′-G  A  A  G  A  C  A  T  C  A  T  C  C  G  G  A  A  T  A  -3′) was cloned into pSUPER and pRETRO-
SUPER (Brummelkamp et al., 2002). Stable expression of Bid siRNA was 
achieved by retroviral transduction of cell lines of interest with the pRETRO-SU-
PER construct. For rescue experiments, two silent mutations were introduced in 
the appropriate Bid sequence (5′-G  A  A  G  A  C  A  T  C  A  T  A  A  G  G  A  A  T  A  -3′) using the 
QuikChange site-directed mutagenesis kit to avoid siRNA-mediated silencing.
Transfection and retroviral transduction
Cells were transfected with FuGENE 6 according to the manufacturer’s instruc-
tions (Roche). Unless otherwise indicated, cells were manipulated 20 h after 
transfection. Production of amphotropic retrovirus was done in ΦNX-Ampho 
cells as described previously (Werner et al., 2002). For transduction, virus-
containing packaging cell supernatant was incubated on ice for 10 min with 
10 μg/ml Dotap (Roche) and subsequently incubated with target cells over-
night. Cells were selected with 1 μg/ml puromycin 48 h after transduction.
CLSM
Cells (10
5 per sample) were grown and transfected on glass coverslips in 
6-well plates, washed in PBS, and ﬁ  xed for 30 min with 4% paraformalde-
hyde in PBS. If applicable, cells were incubated for 30 min with 100 nM 
MitoTracker deep red (Invitrogen) before ﬁ  xation. Fixed cells were washed 
in PBS, permeabilized by incubation in PBS with 1% Triton X-100 for 10 min, 
and blocked with 0.5% BSA in TBS-Tween for 1 h. Cells were incubated 
in the same buffer with the appropriate primary antibody and subsequently 
washed three times in TBS-Tween and incubated with Alexa Fluor 594–
conjugated goat anti–mouse IgG (Invitrogen). Next, cells were washed in 
TBS-Tween and mounted on slides using Vectashield (Vector Laboratories). 
All treatments were performed at room temperature. CLSM was performed 
using a TCS SP2 system using a 63× 1.32 NA oil immersion objective and 
confocal software (all obtained from Leica). Images were processed (crop-
ping and level adjustment) using Photoshop software (Adobe). To minimize 
spectral leak-through, images were obtained by sequential scanning.
Cyt c release assay
Cells were analyzed for Cyt c release essentially as described previously 
(Waterhouse and Trappani, 2003). All cells were collected, washed in 
PBS, and permeabilized with 200 μg/ml digitonin in PBS, 150 mM KCl, 
and 1 mM EDTA for 10 min on ice. Cells were washed once in PBS, ﬁ  xed 
in 4% paraformaldehyde, incubated in blocking buffer (2% BSA in PBS) for 
30 min at room temperature, and incubated with anti–Cyt c mAb 6H2.B4 
at 1:200 dilution in blocking buffer overnight at 4°C. Cells were washed 
in blocking buffer and incubated with a Cy5-conjugated goat anti–mouse 
Ig antibody (Invitrogen) at 1:200 dilution in blocking buffer for 1 h at room 
temperature. After washing, cells were analyzed using a FACSCalibur and 
CellQuest software (BD Biosciences). Cyt c content was analyzed speciﬁ  -
cally in transfected cells by gating the GFP-positive population.
Online supplemental material
Fig. S1 shows the structure of full-length human Bid as determined by NMR 
(Chou et al., 1999; McDonnell et al., 1999), its amino acid sequence, and 
sequence homology of tBid-N between species. Fig. S2 provides the evi-
dence that Bid, rather than the TAP tag, is ubiquitinated. Fig. S3 shows the 
stability assays for alanine substitutions mutants of HA tBid-N TEV 30 per-
formed by incubating transfected HeLa cells with CHX. Fig. S4 demon-
strates that reduction (β-mercaptoethanol) or pH 12 treatment does not 
result in loss of ubiquitin from Ring1b, which carries ubiquitin on lysine 
(Buchwald et al. 2006). Fig. S5 shows MCF-7 Bid RNAi cells expressing 
Myc Bid GFP at different time points after stimulation with TNF-α.
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